BSE · 531686
Advik Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-1 Cr — a -1881.58% net margin, versus -887.23% the period before.
Shareholding
As of 2026-06-30
- Promoter35.89%
- Public63.53%
- DII0.58%
4,409 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.57× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 4. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #43 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 423.85 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,264 Cr | 326.41 | 19.62 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.51 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Advik Laboratories Ltd.(this company) | ₹4 Cr | — | 50.86 | -1489.05% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAdvik Laboratories Ltd. has a market capitalization of Rs 4 Cr. The company's book value per share is Rs 0.04 and it has a debt-to-equity ratio of 4.83. Revenue for the latest period was Rs 0.05 Cr.
Positives
- +No DII or FII selling is recorded in the available shareholding data.
- +The total number of shareholders has decreased from 5012 in Jun 2016 to 4419 in Mar 2026.
Negatives
- −The company has a very low market capitalization of Rs 4 Cr.
- −The debt-to-equity ratio is high at 4.83.
- −Promoter holding has decreased from 55.12% in Dec 2017 to 35.89% in Mar 2026.
- −The company has negative Roe of -1489.05% and negative Roce of -13.92%.
- −The profit margin is 0%, with all recent annual and quarterly net profits being negative.
- −The company is under 'GSM 4' surveillance.
- −16.04% of promoter shares are pledged.
Financial Performance
Advik Laboratories reported a revenue of Rs 0.05 Cr in the latest period. Over the last five annual periods, revenue has fluctuated, with Rs 0.195 Cr in Mar 2021, Rs 0.290 Cr in Mar 2022, Rs 0.023 Cr in Mar 2023, Rs 0.093 Cr in Mar 2024, and Rs 0.047 Cr in Mar 2025. The company has consistently reported negative net profits, with -0.897 Cr in Mar 2025.
Profitability & Returns
The company reported a negative Return on Equity (ROE) of -1489.05% and a negative Return on Capital Employed (ROCE) of -13.92%. The profit margin for the latest period was 0%. Earnings per share (EPS) have been negative over the last five annual periods, ranging from -2.31 in Mar 2021 to -0.47 in Mar 2025.
Balance Sheet
Advik Laboratories Ltd. has a book value per share of Rs 0.04. The debt-to-equity ratio stands at 4.83. The company has consistently reported negative net profits in annual periods, which impacts retained earnings and overall balance sheet strength.
Ownership & Pledges
As of March 31, 2026, promoter holding was 35.89% and public holding was 63.53%. DIIs held 0.577% of the shares. There were 4419 shareholders. Promoters have pledged 16.04% of their shareholding. Specifically, Omkam Pharmaceuticals Private Limited has pledged 1,100,000 shares, representing 22.44% of their holding as of March 31, 2026.
Regulatory & Surveillance
Advik Laboratories Ltd. is currently under surveillance. The company is classified under 'GSM 4' according to the surveillance measures, indicating heightened scrutiny.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.